In patients with operable breast cancer, treatment with the antiosteolytic agent clodronate appears to reduce the risk of bone metastases, according to a report published in the August 1st issue of the Journal of Clinical Oncology. In addition, use of the drug is associated with a reduction in mortality.
Previous reports have indicated that the drug has a beneficial effect on bone-related outcomes in women with bone metastases or in women who have experienced a breast cancer relapse. However, it was unclear if clodronate was useful in preventing the occurrence of bone metastases in women with primary operable breast cancer. In the current study, Dr. Trevor J. Powles, from the Royal Marsden National Health Service Trust in London, and colleagues assessed the outcomes of 1,069 women with primary operable breast cancer who were randomized to receive clodronate 1,600 mg/day or placebo for two years.
Treatment with the assigned agent began within 6 months of primary therapy and the total median follow-up period was approximately 5.7 years.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!